February 27, 2020 / 1:30 PM / a month ago

BRIEF-Ultragenyx And Kyowa Kirin Announce FDA Acceptance And Priority Review Designation Of Supplemental Biologics License Application For Crysvita

Feb 27 (Reuters) - Ultragenyx Pharmaceutical Inc:

* ULTRAGENYX AND KYOWA KIRIN ANNOUNCE FDA ACCEPTANCE AND PRIORITY REVIEW DESIGNATION OF SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR CRYSVITA® (BUROSUMAB) FOR TUMOR-INDUCED OSTEOMALACIA (TIO)

* ULTRAGENYX PHARMACEUTICAL - FDA ASSIGNED PRIORITY REVIEW DESIGNATION WITH PDUFA TARGET DATE OF JUNE 18, 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below